Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS

Conclusion Ozanimod induced dose-dependent reductions in circulating B- and T-cell counts and differential effects on naive and memory CD4+ and CD8+ T cells and CD19+ B cells. Data characterized with both a novel epigenetic cell-counting method and flow cytometry support ozanimod's MOA. Clinical trial registration: clinicaltrials.gov NCT02797015.

http://nn.neurology.org/cgi/content/short/7/5/e839?rss=1

Source: Neurology Neuroimmunology and Neuroinflammation - July 30, 2020 Category: Neurology Authors: Harris, S., Tran, J. Q., Southworth, H., Spencer, C. M., Cree, B. A. C., Zamvil, S. S. Tags: All Neuropsychology/Behavior Article Source Type: research